Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -5.14
Percentage change -0.94	%

Peers: MDT SYK ABT JNJ BSX EW ZBH GMED TMDX

| Held by: VTI VOO QQQ SPY IVV VUG XLV IHI IWF VHT

Index	NDX, S&P 500	P/E	86.73	EPS (ttm)	6.22	Insider Own	0.61%	Shs Outstand	356.20M	Perf Week	-1.97%
Market Cap	192.19B	Forward P/E	68.72	EPS next Y	7.85	Insider Trans	-6.64%	Shs Float	353.99M	Perf Month	0.54%
Income	2.24B	PEG	4.73	EPS next Q	1.75	Inst Own	86.14%	Short Float	0.98%	Perf Quarter	9.81%
Sales	7.87B	P/S	24.43	EPS this Y	20.09%	Inst Trans	-1.16%	Short Ratio	2.77	Perf Half Y	26.73%
Book/sh	43.75	P/B	12.33	EPS next Y	14.50%	ROA	13.82%	Short Interest	3.46M	Perf Year	64.03%
Cash/sh	11.88	P/C	45.42	EPS next 5Y	18.34%	ROE	15.95%	52W Range	320.22 - 556.23	Perf YTD	59.94%
Dividend Est.	-	P/FCF	327.96	EPS past 5Y	9.71%	ROI	14.39%	52W High	-2.99%	Beta	1.39
Dividend TTM	-	Quick Ratio	3.42	Sales past 5Y	14.41%	Gross Margin	66.98%	52W Low	68.50%	ATR (14)	10.05
Dividend Ex-Date	-	Current Ratio	4.30	EPS Y/Y TTM	46.62%	Oper. Margin	26.24%	RSI (14)	53.12	Volatility	2.07% 1.85%
Employees	13676	Debt/Eq	0.00	Sales Y/Y TTM	14.83%	Profit Margin	28.51%	Recom	1.81	Target Price	567.99
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	34.25%	Payout	0.00%	Rel Volume	0.80	Prev Close	544.72
Sales Surprise	1.63%	EPS Surprise	12.05%	Sales Q/Q	16.88%	Earnings	Oct 17 AMC	Avg Volume	1.25M	Price	539.58
SMA20	-0.40%	SMA50	3.63%	SMA200	19.63%	Trades		Volume	1,007,195	Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$522 → $650
Aug-02-24	Upgrade	Redburn Atlantic	Neutral → Buy	$380 → $510
Jul-10-24	Reiterated	Citigroup	Buy	$462 → $512
May-30-24	Initiated	Goldman	Buy	$500
Nov-17-23	Initiated	HSBC Securities	Buy	$318
Jul-19-23	Initiated	Robert W. Baird	Outperform	$377
Apr-19-23	Reiterated	Wells Fargo	Overweight	$289 → $310
Apr-19-23	Reiterated	Truist	Buy	$300 → $325
Apr-19-23	Reiterated	Stifel	Buy	$285 → $315
Apr-19-23	Reiterated	RBC Capital Mkts	Outperform	$305 → $309
Apr-19-23	Reiterated	Raymond James	Outperform	$270 → $323
Apr-19-23	Reiterated	Morgan Stanley	Equal-Weight	$265 → $285
Apr-19-23	Reiterated	JP Morgan	Overweight	$250 → $335
Apr-19-23	Reiterated	Evercore ISI	In-line	$240 → $270
Apr-19-23	Reiterated	Citigroup	Buy	$305 → $317
Apr-19-23	Reiterated	BTIG Research	Buy	$284 → $313
Apr-19-23	Reiterated	BofA Securities	Buy	$300 → $315
Mar-29-23	Initiated	UBS	Neutral	$278
Mar-23-23	Initiated	William Blair	Outperform
Oct-18-22	Initiated	Barclays	Overweight	$235

Show Previous Ratings

Today 05:50PM	Intuitive Surgical, Inc. (ISRG) Stock Moves -0.94%: What You Should Know (Zacks)
Dec-10-24 04:54AM	Intuitives da Vinci beats non-robotic surgeries in cancer meta-analysis (MedTech Dive)
Dec-09-24 08:42AM	Are Options Traders Betting on a Big Move in Intuitive Surgical (ISRG) Stock? (Zacks)
Dec-06-24 09:00AM	Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock (Zacks)
Dec-05-24 04:15PM	Meta-analysis published in Annals of Surgery shows benefits of da Vinci surgery across seven oncologic procedures compared to laparoscopic and open (GlobeNewswire)
05:50PM	Loading…
Dec-04-24 05:50PM	Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
08:45AM	Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That's Expected to be a $7.2 Billion Market by 2029 (GlobeNewswire)
Dec-03-24 02:05PM	Intuitive Surgical, Inc. (ISRG): A Bull Case Theory (Insider Monkey)
12:47PM	These are the sectors investors need to watch (Yahoo Finance Video)
12:00PM	Intuitive Surgical (ISRG) Upgraded to Buy: Here's What You Should Know (Zacks)
05:00AM	How CMR Surgical is taking on robotics 800-pound gorilla (MedTech Dive)
Dec-02-24 02:29PM	Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos (Benzinga)
06:00AM	Invest with Confidence: Intrinsic Value Unveiled of Intuitive Surgical Inc (GuruFocus.com)
Nov-28-24 07:45AM	2 Excellent Healthcare Stocks to Hold Through the Next Decade (Motley Fool)
Nov-25-24 09:30AM	Wall Street Bulls Look Optimistic About Intuitive Surgical (ISRG): Should You Buy? (Zacks)
09:00AM	Loading…
09:00AM	Is Trending Stock Intuitive Surgical, Inc. (ISRG) a Buy Now? (Zacks)
Nov-18-24 09:15PM	The Art of Valuation: Discovering Intuitive Surgical Inc's Intrinsic Value (GuruFocus.com)
09:40AM	Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-16-24 10:04AM	Ignore The Valuation And Buy The Growth In Intuitive Surgical (ISRG) (Insider Monkey)
Nov-13-24 11:58AM	J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot (Medical Device Network)
Nov-12-24 09:00AM	Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Nov-10-24 05:48AM	Intuitive Surgical (ISRG): The Hidden Gem in Robotics Stocks Dominating Healthcare (Insider Monkey)
Nov-09-24 05:14AM	3 Soaring Stocks to Hold for the Next 20 Years (Motley Fool)
Nov-08-24 09:30AM	Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It? (Zacks)
Nov-05-24 12:40PM	3 Robotic Stocks To Play AI As Nvidia Rally Slows (Insider Monkey)
Nov-04-24 06:00AM	Unlocking Intrinsic Value: Analysis of Intuitive Surgical Inc (GuruFocus.com)
Nov-01-24 09:00AM	Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Oct-30-24 12:32PM	Why IBD Stock Of The Day Intuitive Surgical Is Eyeing Yet Another Breakout (Investor's Business Daily)
09:47AM	Intuitive Surgical, Inc. (ISRG): Among UBS Top Tech Based Disruptive Stocks For 2030 (Insider Monkey)
Oct-28-24 07:00AM	Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner (PR Newswire)
07:00AM	Loading…
Oct-25-24 07:00AM	Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever. (Motley Fool)
Oct-23-24 09:30AM	Intuitive Surgical (ISRG) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
04:28AM	Has Intuitive Surgical (NASDAQ:ISRG) Stocks Valuation Gotten Out of Hand? (TipRanks)
Oct-22-24 09:53AM	Up 800% the Past Decade, Can the Momentum Continue for This Hot Stock? (Motley Fool)
Oct-21-24 05:00PM	Eaton Vance Worldwide Health Sciences Fund Sharpens Focus on Humana Inc in Q3 2024 (GuruFocus.com)
04:05PM	AI Leaders Broadcom And SentinelOne Lead 5 Stocks Near Buy Points (Investor's Business Daily)
02:24PM	AI Leaders Broadcom, SentinelOne Lead 5 Stocks Near Buy Points (Investor's Business Daily)
09:00AM	Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:00AM	Navigating Market Uncertainty: Intrinsic Value of Intuitive Surgical Inc (GuruFocus.com)
Oct-19-24 07:52AM	Intuitive Surgical price target raised to $525 from $475 at Stifel (TipRanks)
01:04AM	Decoding Intuitive Surgical Inc (ISRG): A Strategic SWOT Insight (GuruFocus.com)
Oct-18-24 07:30PM	Compared to Estimates, Intuitive Surgical (ISRG) Q3 Earnings: A Look at Key Metrics (Zacks) +10.01%
04:32PM	Intuitive Surgical stock moves higher on Q3 earnings beat (Yahoo Finance Video)
04:28PM	Intuitive Surgical Breaks Out On Massive Earnings Beat, But 2025 Launch Remains Key (Investor's Business Daily)
04:22PM	Intuitive Surgical Shares Surge 6% as Q3 Earnings Beat Expectations (GuruFocus.com)
03:26PM	Intuitive Surgical (ISRG): Financial Growth Fueled by AI-Driven Da Vinci Systems (Insider Monkey)
02:54PM	Robotic Surgery Leader, Mobile Carrier Jump To New Highs (Investor's Business Daily)
12:48PM	Intuitive Surgical Surges 9% on Strong Q3 Results and Regulatory Wins (GuruFocus.com)
11:38AM	Intuitive Surgical Stock Pops on Earnings Beat. What Wall Street Thinks of the Results. (Barrons.com)
10:14AM	Intuitive Surgical Stock Hits Record High on da Vinci Device Demand (Investopedia)
09:27AM	Intuitive Surgical Eyes Breakout On Massive Earnings Beat, But 2025 Launch Remains Key (Investor's Business Daily)
07:16AM	Q3 2024 Intuitive Surgical Inc Earnings Call (Thomson Reuters StreetEvents)
05:01AM	Analyst Report: Intuitive Surgical, Inc. (Morningstar Research)
04:34AM	Intuitive Surgical shares jump 6% after Q3 earnings beat, da Vinci ramp (Investing.com)
03:04AM	Intuitive Surgical Inc (ISRG) Q3 2024 Earnings Call Highlights: Strong Revenue and Procedure ... (GuruFocus.com)
Oct-17-24 09:15PM	Intuitive Surgical (ISRG) Q3 2024 Earnings Call Transcript (Motley Fool)
05:15PM	Intuitive Surgical, Inc. (ISRG) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:54PM	Intuitive Surgical Adds To 40% Run With Massive Profit Beat, Strong Procedure Growth (Investor's Business Daily)
04:05PM	Intuitive Announces Third Quarter Earnings (GlobeNewswire)
01:20PM	Intuitive Surgical's Earnings Are On Deck. Will Its 41% Surge Remain Intact? (Investor's Business Daily)
Oct-16-24 12:10PM	Will Intuitive Surgical (ISRG) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-15-24 12:33PM	Analysts reboot Intuitive Surgical stock price target ahead of earnings (TheStreet)
Oct-14-24 09:15AM	Intuitive Surgical (ISRG) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Oct-13-24 06:00AM	What To Expect in the Markets This Week (Investopedia)
Oct-11-24 11:39PM	RBC Capital Raises Intuitive Surgical, Inc. (ISRG) Price Target to $525, Maintains Outperform Rating Amid Positive Q3 Utilization Trends in MedTech (Insider Monkey)
06:45AM	2 Soaring Growth Stocks Up 45% and 60% in 2024 to Buy Right Now (Motley Fool)
Oct-09-24 06:00PM	Intuitive Surgical, Inc. (ISRG) Outperforms Broader Market: What You Need to Know (Zacks)
04:47PM	LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Streets Strong Buy Rating? (TipRanks)
02:33AM	Intuitive Surgical, Inc. (ISRG): Stock That Will Make You Rich in 5-10 Years (Insider Monkey)
Oct-07-24 09:00AM	Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Oct-04-24 01:22PM	Is Intuitive Surgical, Inc. (NASDAQ:ISRG) The Top Goldman Sachs Fund Manager Stock Pick? (Insider Monkey)
09:30AM	Wall Street Analysts See Intuitive Surgical (ISRG) as a Buy: Should You Invest? (Zacks)
08:00AM	Unlocking Intrinsic Value: Analysis of Intuitive Surgical Inc (GuruFocus.com)
Oct-03-24 08:30AM	Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. (Investor's Business Daily)
Oct-01-24 06:00PM	Intuitive Surgical, Inc. (ISRG) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
08:00AM	These Are The Best Second-Chance Stocks Around (Investor's Business Daily)
Sep-28-24 09:56PM	Jim Cramer Prefers Intuitive Surgical, Inc. (NASDAQ:ISRG) Over Procept Biorobotics (Insider Monkey)
Sep-25-24 06:00PM	Intuitive Surgical, Inc. (ISRG) Flat As Market Sinks: What You Should Know (Zacks)
08:29AM	Intuitive Surgical, Inc. (ISRG): Hedge Funds Are Bullish On This Trending AI Stock Right Now (Insider Monkey)
Sep-24-24 09:00AM	Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Sep-21-24 06:20AM	Bull Market Buys: 2 Nasdaq Stocks to Own for the Long Run (Motley Fool)
Sep-20-24 10:00AM	Intuitive Surgical Has Stellar Performance, but Is Priced to Perfection (GuruFocus.com)
08:00AM	Intuitive Surgical Inc: An Exploration into Its Intrinsic Value (GuruFocus.com)
Sep-19-24 05:50PM	Here's Why Intuitive Surgical, Inc. (ISRG) Gained But Lagged the Market Today (Zacks)
Sep-18-24 09:30AM	Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views? (Zacks)
08:16AM	Intuitive Surgical, Inc. (ISRG): A Bear Case Theory (Insider Monkey)
08:00AM	CIBC introduces additional Canadian Depositary Receipts ("CDRs") (PR Newswire)
Sep-17-24 06:00PM	Intuitive Surgical, Inc. (ISRG) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Sep-12-24 10:54AM	Intuitive Surgical, Inc. (ISRG): A Very Important AI Stock According to BlackRock (Insider Monkey)
Sep-11-24 05:50PM	Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts (Zacks)
09:00AM	Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Sep-06-24 07:51AM	Jim Cramer Says I Think If Youre Going To Be In Robotics, You Have To Be In Intuitive Surgical Inc. (ISRG) (Insider Monkey)
Sep-05-24 05:50PM	Intuitive Surgical, Inc. (ISRG) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
08:00AM	Unlocking Intrinsic Value: Analysis of Intuitive Surgical Inc (GuruFocus.com)
Sep-04-24 06:00PM	Intuitive Surgical, Inc. (ISRG) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Sep-02-24 05:07PM	Intuitive Surgical, Inc. (ISRG): A Good 52-Week High Stock to Buy According to Short Sellers (Insider Monkey)
Aug-30-24 09:00AM	2 Top Healthcare Growth Stocks to Buy Right Now (Motley Fool)
Aug-29-24 05:50PM	Intuitive Surgical, Inc. (ISRG) Stock Moves 1.03%: What You Should Know (Zacks)
Aug-28-24 06:53PM	Intuitive Surgical, Inc. (ISRG): Among The Best Medical AI Companies (Insider Monkey)
09:00AM	Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know (Zacks)

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Samath Jamie	CFO and Head of Business Techn	Dec 10 '24	Option Exercise	267.03	270	72,098	8,892	Dec 11 12:50 PM
Samath Jamie	CFO and Head of Business Techn	Dec 10 '24	Sale	540.15	270	145,842	8,757	Dec 11 12:50 PM
JAMIE E SAMATH	Officer	Dec 10 '24	Proposed Sale	540.15	270	145,842		Dec 10 04:02 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Nov 29 '24	Option Exercise	249.61	376	93,855	5,694	Dec 02 01:48 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Nov 29 '24	Sale	539.00	376	202,664	5,506	Dec 02 01:48 PM
Samath Jamie	CFO and Head of Business Techn	Nov 29 '24	Option Exercise	249.61	188	46,928	8,851	Dec 02 01:35 PM
Samath Jamie	CFO and Head of Business Techn	Nov 29 '24	Sale	539.00	188	101,332	8,757	Dec 02 01:35 PM
JAMIE E SAMATH	Officer	Nov 29 '24	Proposed Sale	539.00	188	101,332		Nov 29 01:27 PM
ROBERT DESANTIS	Officer	Nov 29 '24	Proposed Sale	539.00	376	202,664		Nov 29 01:25 PM
Samath Jamie	CFO and Head of Business Techn	Nov 26 '24	Option Exercise	296.51	108	32,023	8,811	Nov 26 06:03 PM
Samath Jamie	CFO and Head of Business Techn	Nov 26 '24	Sale	542.06	108	58,542	8,757	Nov 26 06:03 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Nov 26 '24	Option Exercise	296.51	396	117,417	5,704	Nov 26 05:42 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Nov 26 '24	Sale	542.06	396	214,656	5,506	Nov 26 05:42 PM
JAMIE E SAMATH	Officer	Nov 26 '24	Proposed Sale	542.06	108	58,542		Nov 26 04:08 PM
ROBERT DESANTIS	Officer	Nov 26 '24	Proposed Sale	542.06	396	214,656		Nov 26 04:06 PM
Curet Myriam	EVP & Chief Medical Officer	Nov 12 '24	Option Exercise	197.39	13,466	2,658,000	5,298	Nov 13 04:21 PM
Curet Myriam	EVP & Chief Medical Officer	Nov 12 '24	Sale	535.96	13,466	7,217,196	298	Nov 13 04:21 PM
Samath Jamie	See Remarks	Nov 08 '24	Option Exercise	245.13	22,903	5,614,260	31,660	Nov 12 07:16 PM
Samath Jamie	See Remarks	Nov 11 '24	Option Exercise	266.89	269	71,793	9,026	Nov 12 07:16 PM
Samath Jamie	See Remarks	Nov 08 '24	Sale	525.00	22,903	12,024,075	8,757	Nov 12 07:16 PM
Samath Jamie	See Remarks	Nov 11 '24	Sale	539.89	269	145,230	8,757	Nov 12 07:16 PM
MYRIAM CURET MCADAMS	Officer	Nov 12 '24	Proposed Sale	535.96	13,466	7,217,196		Nov 12 04:06 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Nov 11 '24	Option Exercise	267.19	239	63,858	5,626	Nov 12 01:34 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Nov 11 '24	Sale	539.89	239	129,034	5,506	Nov 12 01:34 PM
JAMIE E SAMATH	Officer	Nov 11 '24	Proposed Sale	539.89	269	145,230		Nov 12 11:43 AM
ROBERT DESANTIS	Officer	Nov 11 '24	Proposed Sale	539.89	239	129,034		Nov 12 11:42 AM
JAMIE E SAMATH	Officer	Nov 08 '24	Proposed Sale	525.00	22,903	12,024,075		Nov 08 04:17 PM
GUTHART GARY S	CEO	Oct 30 '24	Option Exercise	59.23	25,200	1,492,541	42,370	Oct 31 12:22 PM
GUTHART GARY S	CEO	Oct 30 '24	Sale	511.63	18,151	9,286,674	24,219	Oct 31 12:22 PM
GUTHART GARY S	CEO	Oct 30 '24	Sale	510.64	7,440	3,799,129	19,920	Oct 31 12:22 PM
GARY S GUTHART	Officer	Oct 30 '24	Proposed Sale	511.63	18,151	9,286,672		Oct 30 04:25 PM
GUTHART GARY S	Officer	Oct 30 '24	Proposed Sale	516.31	7,440	3,841,346		Oct 30 10:44 AM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Oct 25 '24	Option Exercise	272.09	1,012	275,360	5,704	Oct 29 06:55 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Oct 28 '24	Option Exercise	294.52	584	171,999	5,704	Oct 29 06:55 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Oct 29 '24	Option Exercise	208.90	188	39,273	5,694	Oct 29 06:55 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Oct 25 '24	Sale	514.00	1,012	520,168	5,506	Oct 29 06:55 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Oct 28 '24	Sale	513.66	584	299,977	5,506	Oct 29 06:55 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Oct 29 '24	Sale	506.52	188	95,226	5,506	Oct 29 06:55 PM
ROBERT DESANTIS	Officer	Oct 29 '24	Proposed Sale	506.52	188	95,226		Oct 29 04:02 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Oct 25 '24	Sale	514.00	22	11,308	207	Oct 28 04:29 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Oct 28 '24	Sale	513.66	22	11,301	185	Oct 28 04:29 PM
MARK BROSIUS	Officer	Oct 28 '24	Proposed Sale	513.66	22	11,301		Oct 28 04:05 PM
ROBERT DESANTIS	Officer	Oct 28 '24	Proposed Sale	513.66	584	299,977		Oct 28 04:04 PM
MARK BROSIUS	Officer	Oct 25 '24	Proposed Sale	514.00	22	11,308		Oct 25 04:11 PM
ROBERT DESANTIS	Officer	Oct 25 '24	Proposed Sale	514.00	1,012	520,168		Oct 25 04:11 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Oct 22 '24	Option Exercise	77.00	2,106	162,160	2,401	Oct 24 05:58 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Oct 22 '24	Sale	515.00	2,128	1,095,920	273	Oct 24 05:58 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Oct 23 '24	Sale	513.89	22	11,306	251	Oct 24 05:58 PM
Brosius Mark	SVP & Chief Mfg and Supply Cha	Oct 24 '24	Sale	510.79	22	11,237	229	Oct 24 05:58 PM
MARK BROSIUS	Officer	Oct 24 '24	Proposed Sale	510.79	22	11,237		Oct 24 04:08 PM
MARK BROSIUS	Officer	Oct 23 '24	Proposed Sale	513.89	22	11,306		Oct 23 04:02 PM
Miller Brian Edward	EVP & Chief Digital Officer	Oct 22 '24	Sale	515.00	2,553	1,314,795	7,066	Oct 23 07:38 AM
BRIAN MILLER	Officer	Oct 22 '24	Proposed Sale	515.00	2,553	1,314,795		Oct 22 04:02 PM
MARK BROSIUS	Officer	Oct 22 '24	Proposed Sale	515.00	2,128	1,095,920		Oct 22 04:01 PM
MOHR MARSHALL	Officer	Oct 22 '24	Proposed Sale	515.00	29,787	15,340,305		Oct 22 01:01 PM
LOEB GARY	General Counsel	Oct 10 '24	Option Exercise	0.00	2,613	0	4,208	Oct 10 02:36 PM
Ladd Amy L	Director	Sep 13 '24	Sale	490.28	450	220,626	821	Sep 16 12:30 PM
Brosius Mark	See Remarks	Sep 12 '24	Option Exercise	59.46	2,115	125,763	2,410	Sep 16 12:29 PM
Brosius Mark	See Remarks	Sep 12 '24	Sale	491.91	2,115	1,040,390	295	Sep 16 12:29 PM
AMY L LADD	Director	Sep 13 '24	Proposed Sale	490.28	450	220,626		Sep 13 04:08 PM
MARK BROSIUS	Officer	Sep 12 '24	Proposed Sale	491.91	2,115	1,040,390		Sep 12 04:52 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Sep 10 '24	Option Exercise	267.03	238	63,553	5,625	Sep 10 07:07 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Sep 10 '24	Sale	477.50	238	113,645	5,506	Sep 10 07:07 PM
ROBERT DESANTIS	Officer	Sep 10 '24	Proposed Sale	477.50	238	113,645		Sep 10 04:01 PM
LOEB GARY	General Counsel	Sep 09 '24	Sale	475.00	300	142,500	1,595	Sep 09 06:38 PM
GARY LOEB	Officer	Sep 09 '24	Proposed Sale	475.00	300	142,500		Sep 09 04:02 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 28 '24	Option Exercise	290.33	188	54,582	5,694	Aug 29 05:49 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 29 '24	Option Exercise	208.90	188	39,273	5,694	Aug 29 05:49 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 28 '24	Sale	482.93	188	90,791	5,506	Aug 29 05:49 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 29 '24	Sale	482.21	188	90,655	5,506	Aug 29 05:49 PM
ROBERT DESANTIS	Officer	Aug 29 '24	Proposed Sale	482.21	188	90,655		Aug 29 04:16 PM
ROBERT DESANTIS	Officer	Aug 28 '24	Proposed Sale	482.93	188	90,791		Aug 28 04:22 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 26 '24	Option Exercise	296.51	396	117,417	5,704	Aug 26 06:49 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 26 '24	Sale	486.88	396	192,804	5,506	Aug 26 06:49 PM
Charlton Henry L	SVP & Chief Commercial and Mkt	Aug 23 '24	Option Exercise	142.20	19,758	2,809,518	28,689	Aug 26 05:04 PM
Charlton Henry L	SVP & Chief Commercial and Mkt	Aug 23 '24	Sale	486.84	40,243	19,591,843	3,001	Aug 26 05:04 PM
ROBERT DESANTIS	Officer	Aug 26 '24	Proposed Sale	486.88	396	192,804		Aug 26 04:03 PM
HENRY CHARLTON	Officer	Aug 23 '24	Proposed Sale	486.84	40,243	19,591,840		Aug 23 04:13 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 12 '24	Option Exercise	267.03	240	64,087	5,626	Aug 13 02:13 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Aug 12 '24	Sale	464.76	240	111,542	5,506	Aug 13 02:13 PM
ROBERT DESANTIS	Officer	Aug 12 '24	Proposed Sale	464.76	240	111,542		Aug 12 04:10 PM
Johnson Amal M	Director	Aug 01 '24	Option Exercise	71.32	2,943	209,904	15,218	Aug 05 01:10 PM
Johnson Amal M	Director	Aug 01 '24	Sale	443.30	2,943	1,304,632	12,275	Aug 05 01:10 PM
AMAL M JOHNSON	Director	Aug 01 '24	Proposed Sale	443.30	2,943	1,304,632		Aug 01 04:15 PM
GUTHART GARY S	CEO	Jul 30 '24	Option Exercise	57.11	25,200	1,439,200	40,558	Jul 31 01:24 PM
GUTHART GARY S	CEO	Jul 30 '24	Sale	443.07	23,388	10,362,516	17,170	Jul 31 01:24 PM
GUTHART GARY S	CEO	Jul 30 '24	Sale	445.09	7,440	3,311,480	23,640	Jul 31 01:24 PM
GARY S GUTHART	Officer	Jul 30 '24	Proposed Sale	443.07	23,388	10,362,514		Jul 30 04:38 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Jul 26 '24	Option Exercise	279.09	1,413	394,347	5,905	Jul 30 02:02 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Jul 29 '24	Option Exercise	249.61	376	93,855	5,694	Jul 30 02:02 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Jul 26 '24	Sale	438.60	1,413	619,742	5,506	Jul 30 02:02 PM
DeSantis Robert	EVP & Chief Strategy & Corp Op	Jul 29 '24	Sale	446.60	376	167,922	5,506	Jul 30 02:02 PM
GUTHART GARY S	Officer	Jul 30 '24	Proposed Sale	442.05	7,440	3,288,852		Jul 30 10:55 AM
ROBERT DESANTIS	Officer	Jul 29 '24	Proposed Sale	446.60	376	167,922		Jul 29 04:36 PM
ROBERT DESANTIS	Officer	Jul 26 '24	Proposed Sale	438.60	1,413	619,742		Jul 26 04:35 PM
BARRATT CRAIG H	Director	Jul 23 '24	Option Exercise	56.97	1,400	79,764	1,400	Jul 24 02:06 PM
BARRATT CRAIG H	Director	Jul 23 '24	Sale	458.13	1,400	641,382	0	Jul 24 02:06 PM
Curet Myriam	EVP & Chief Medical Officer	Jul 23 '24	Option Exercise	177.99	2,818	501,567	3,116	Jul 24 01:47 PM
Curet Myriam	EVP & Chief Medical Officer	Jul 23 '24	Sale	458.13	2,818	1,291,010	298	Jul 24 01:47 PM
BARRATT CRAIG H	Director	Jun 12 '24	Option Exercise	56.97	1,400	79,764	1,400	Jun 12 09:18 PM

Open in Screener

NKTR

Nektar Therapeutics

Dec 13 • 04:00PM ET

1.01

Dollar change +0.01
Percentage change 1.00	%

Healthcare • Biotechnology • USA • NASD

NKTR Nektar Therapeutics daily Stock Chart

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI IWM VXF IWN VTWO SCHA VHT PRFZ IWC FESM

Index	RUT	P/E	-	EPS (ttm)	-0.84	Insider Own	3.38%	Shs Outstand	184.46M	Perf Week	-0.98%
Market Cap	186.30M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	-1.23%	Shs Float	178.22M	Perf Month	-21.09%
Income	-168.30M	PEG	-	EPS next Q	-0.13	Inst Own	74.38%	Short Float	2.49%	Perf Quarter	-20.47%
Sales	93.14M	P/S	2.00	EPS this Y	51.45%	Inst Trans	3.98%	Short Ratio	2.63	Perf Half Y	-13.68%
Book/sh	0.27	P/B	3.81	EPS next Y	-5.38%	ROA	-44.87%	Short Interest	4.44M	Perf Year	102.45%
Cash/sh	1.33	P/C	0.76	EPS next 5Y	-7.30%	ROE	-161.63%	52W Range	0.46 - 1.93	Perf YTD	78.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-72.09%	52W High	-47.61%	Beta	0.57
Dividend TTM	-	Quick Ratio	4.24	Sales past 5Y	-20.42%	Gross Margin	67.80%	52W Low	121.98%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	4.24	EPS Y/Y TTM	46.09%	Oper. Margin	-145.91%	RSI (14)	37.99	Volatility	5.03% 6.92%
Employees	137	Debt/Eq	4.22	Sales Y/Y TTM	5.53%	Profit Margin	-180.70%	Recom	2.50	Target Price	4.16
Option/Short	Yes / Yes	LT Debt/Eq	3.78	EPS Q/Q	26.42%	Payout	-	Rel Volume	1.22	Prev Close	1.00
Sales Surprise	25.81%	EPS Surprise	9.55%	Sales Q/Q	-0.08%	Earnings	Nov 07 AMC	Avg Volume	1.69M	Price	1.01
SMA20	-3.76%	SMA50	-17.10%	SMA200	-19.95%	Trades		Volume	2,058,410	Change	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform	$18 → $6
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform	$21
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy	$20
Sep-10-21	Initiated	BofA Securities	Neutral	$18

Show Previous Ratings

Dec-07-24 12:00PM	Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting (PR Newswire)
Nov-18-24 03:30PM	Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence (PR Newswire)
Nov-08-24 02:30AM	Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook (GuruFocus.com)
Nov-07-24 05:40PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:36PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Loading…
04:15PM	Nektar Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire)
10:15AM	Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Nov-06-24 06:00PM	Nektar Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-05-24 10:34AM	Nektar Therapeutics to sell Alabama facility to Ampersand (Pharmaceutical Technology) +5.26%
Nov-04-24 01:44PM	Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential (Benzinga) +8.13%
08:30AM	Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama (PR Newswire)
Oct-31-24 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-29-24 09:00AM	Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases (PR Newswire) -6.62%
Oct-17-24 12:07PM	Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (PR Newswire) +5.07%
Sep-25-24 03:30AM	Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 (PR Newswire)
09:00AM	Loading…
Sep-03-24 09:00AM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire)
Aug-13-24 12:00PM	What Makes Nektar (NKTR) a New Buy Stock (Zacks)
Aug-09-24 10:58AM	Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top (Zacks) -8.26%
Aug-08-24 05:55PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:49PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.22% -5.51%
Jun-12-24 09:30AM	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 (PR Newswire)
May-30-24 06:00PM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire) -8.70%
May-10-24 04:41PM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.00%
03:14PM	Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview (GuruFocus.com)
11:33AM	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates (Zacks)
10:35AM	Q1 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:39PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
06:00PM	Loading…
May-02-24 06:00PM	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.99%
Apr-03-24 11:30AM	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks) +9.47%
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 02:00PM	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-06-24 12:33PM	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata (Zacks)
Mar-05-24 10:07AM	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat (Zacks)
09:13AM	Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata (PR Newswire)
07:19AM	Q4 2023 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 05:30PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.38%
04:51PM	Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results (GuruFocus.com)
04:42PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
08:30AM	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX (PR Newswire)
Feb-27-24 06:00PM	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference (PR Newswire) +11.94%
Feb-26-24 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-20-24 10:00AM	Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know (Zacks) -6.78%
Jan-03-24 06:00PM	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) -6.36%
Dec-11-23 06:00PM	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire) -5.94%
Dec-07-23 11:31AM	Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 08:39AM	Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.00%
Nov-08-23 11:47AM	Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss (Zacks) -8.76%
Nov-07-23 05:28PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-31-23 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-26-23 10:02AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -7.11%
Oct-13-23 08:30AM	Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress (PR Newswire)
Oct-02-23 09:00AM	Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy (PR Newswire)
Sep-27-23 09:00AM	Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Sep-14-23 07:54AM	Nektar (NKTR) Up on Positive New Data From Eczema Study (Zacks)
Sep-13-23 09:00AM	Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Sep-07-23 11:31AM	Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report? (Zacks)
Sep-06-23 06:00PM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th (PR Newswire)
Aug-17-23 07:02PM	RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics (GuruFocus.com) -6.26%
Aug-09-23 09:25AM	Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss (Zacks) -8.94%
Aug-08-23 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Nektar: Q2 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
11:08AM	Nektar Therapeutics sues Lilly for breach of contract around skin drug (American City Business Journals)
Aug-07-23 10:23AM	Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment (Reuters) +91.51%
06:30AM	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company (PR Newswire)
Aug-01-23 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Jul-24-23 03:48AM	Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last? (Zacks) -5.69%
Jul-16-23 08:49AM	Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company (Simply Wall St.)
Jun-12-23 06:00PM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
Jun-08-23 12:55PM	Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel (Simply Wall St.)
11:31AM	Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report? (Zacks)
May-10-23 11:28AM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript (Insider Monkey)
09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
May-09-23 06:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Nektar: Q1 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
May-08-23 09:29AM	Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More (Zacks) -5.94%
May-04-23 10:00AM	Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline (Zacks)
May-02-23 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-27-23 08:30AM	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development (PR Newswire)
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-17-23 05:00PM	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan (PR Newswire) +6.26% -5.67%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Apr-13-23 10:59AM	Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio (Zacks) +10.16%
Apr-11-23 08:57AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics (Zacks) +10.53%
Apr-10-23 10:07AM	5 Stocks to Buy as the Drug Industry Rebounds in 2023 (Zacks) +6.57%
Apr-02-23 08:27AM	We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? (Zacks) -12.42%
Mar-29-23 05:44PM	Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 (PR Newswire)
Mar-24-23 12:00PM	Nektar (NKTR) Upgraded to Buy: Here's Why (Zacks)
Mar-22-23 09:35AM	Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR) (Zacks) -9.73%
Mar-14-23 03:43AM	Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Feb-28-23 05:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results (PR Newswire) +9.42%

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Nov 19 '24	Sale	1.01	7,785	7,863	243,019	Nov 20 08:37 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 19 '24	Sale	1.01	6,407	6,471	218,856	Nov 20 08:36 PM
ROBIN HOWARD W	President & CEO	Nov 19 '24	Sale	1.01	16,278	16,441	832,080	Nov 20 08:36 PM
Zalevsky Jonathan	Officer	Nov 19 '24	Proposed Sale	1.01	7,785	7,878		Nov 19 04:10 PM
Wilson Mark Andrew	Officer	Nov 19 '24	Proposed Sale	1.01	6,407	6,483		Nov 19 03:28 PM
ROBIN HOWARD W	Officer	Nov 19 '24	Proposed Sale	1.01	16,278	16,472		Nov 19 03:17 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '24	Sale	1.28	6,866	8,788	250,804	Aug 20 09:15 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '24	Sale	1.28	5,651	7,233	225,263	Aug 20 09:15 PM
ROBIN HOWARD W	President & CEO	Aug 19 '24	Sale	1.28	14,881	19,048	848,358	Aug 20 09:14 PM
Wilson Mark Andrew	Officer	Aug 19 '24	Proposed Sale	1.28	5,651	7,211		Aug 19 04:13 PM
ROBIN HOWARD W	Officer	Aug 19 '24	Proposed Sale	1.28	14,881	18,990		Aug 19 04:03 PM
Zalevsky Jonathan	Officer	Aug 19 '24	Proposed Sale	1.28	6,866	8,762		Aug 19 03:45 PM
CHESS ROBERT	Director	Jun 14 '24	Sale	1.20	19,500	23,400	255,273	Jun 14 06:02 PM
ROBIN HOWARD W	President & CEO	May 17 '24	Sale	1.75	16,650	29,138	863,239	May 20 09:14 PM
Zalevsky Jonathan	Chief R&D Officer	May 17 '24	Sale	1.75	7,355	12,871	257,670	May 20 09:13 PM
Wilson Mark Andrew	Chief Legal Officer	May 17 '24	Sale	1.75	6,260	10,955	230,414	May 20 09:12 PM
Deep Track Capital, LP	10% Owner	May 10 '24	Sale	1.78	56,000	99,630	18,344,000	May 13 04:36 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 20 '24	Sale	0.68	9,014	6,130	265,025	Feb 22 08:19 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 20 '24	Sale	0.68	7,606	5,172	236,674	Feb 22 08:17 PM
ROBIN HOWARD W	President & CEO	Feb 20 '24	Sale	0.68	20,033	13,622	879,889	Feb 22 08:16 PM

ISRG

Intuitive Surgical Inc

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience